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AbstrAct:
Using the Hey3Met2 human ovarian cancer cell line, we previously found the RNASET2 
gene to possess a remarkable in vivo tumor suppressor activity,  although no in vitro 
features such as inhibition of cell proliferation, clonogenic potential, impaired growth 
in soft agar  and increase in apoptotic rate could be detected. This is reminiscent of the 
behavior of genes belonging to the class of  tumor antagonizing genes (TAG) which act 
mainly within the context of the microenvironment. Here we present transcriptional 
profiles  analysis  which  indicates  that  investigations  of  the  mechanisms  of  TAG 
biological functions require a comparison between the in vitro and in vivo expression 
patterns. Indeed several genes displaying a biological function  potentially related 
to tumor suppression could not be  validated by subsequent in vivo expression 
analysis. On the other hand the fact that we could find congruency for  three genes 
both in vivo and in vitro adds a warning to a too much stringent categorization of 
this class of genes which relies on the sensitivity of the methodological approaches. 
rNAsEt2, A NEW MEMbEr OF 
tHE GrOWING cLAss OF tUMOr 
ANtAGONIZING GENEs
Among the gynaecological malignancies, ovarian 
cancer is considered to be the most lethal tumor, with 
an incidence of 42,000 new cases per year in Europe [1] 
and 22,000 cases in the USA [2]. In more than 60% of 
the patients, the diagnosis is made in advanced stage, 
owing both to the lack of symptoms and the to fact that a 
panel of highly predictive biomarkers for screening and 
early stage detection is still missing. It is estimated that 
80% of the patients with advanced disease will develop 
recurrence and succumb to the illness, despite their good 
initial responsiveness to primary therapy.
We reckon that one of the main reasons for such 
regrettable scenario is a poor understanding of the 
biological bases of ovarian cancer pathogenesis. Indeed, 
one of the salient feature of these tumors is their high 
heterogeneity, both at the morphological and biological 
levels, which make the contribution of genetic lesions 
difficult to interpret in a causative way. Among human 
cancers located in the ovary, those derived from the 
ovarian surface epithelium are the most frequent [3] and 
all epithelial ovarian cancer subtypes have been postulated 
to originate from the single layer of cells representing the 
ovary’s surface epithelium (OSE cells) [4]. These cells 
are known to undergo repeated cycles of proliferation 
due to the recurrent growth and rupture of ovarian 
follicles during the ovulatory cycle and one feature of this 
phenomenon is a well characterized interaction between 
the ovarian mesenchymal and surface epithelial cells [5]. 
Any imbalance in the microenviromental homeostasis 
has therefore the potential to contribute to ovarian 
cancerogenesis, and a growing interest has indeed been 
placed toward the active role for stromal misregulation 
in the progression of neoplasias [6]. Within this frame, 
a special class of genes has been recently described that Oncotarget 2011; 2:  477 - 484 478 www.impactjournals.com/oncotarget
seems to play a crucial role in tumor suppression by 
means of regulating the cross-talk between stromal and 
epithelial cells. These genes belong to the growing but 
still poorly characterized class of tumor antagonizing/ 
malignancy suppressor genes (TAG/MSG) [7], whose 
principal feature is their ability to suppress malignant 
growth in vivo but not in vitro.
We have recently reported a preliminary biological 
characterization of one of these genes, called RNASET2, 
which codes for an extracellular RNase highly conserved 
among the phila from viruses to humans, suggesting an 
evolutionary important function [8].
In a xenograph model for ovarian cancer, we found 
RNASET2 to carry out a strong oncosuppressive activity 
by recruiting cells of the monocyte/macrophage lineage 
into the tumour mass. This subset of cells represents the 
main component of the host immunological response [9]. 
Although the main function of RNASET2 was found to 
take place in the context of the microenvironment, namely 
in the extracellular compartment, we could not completely 
rule out that this conserved RNase might also carry out a 
cell-autonomous role, as suggested by a recent work on 
S.Cerevisiae [10]. 
This was basically the rationale that prompted us to 
further investigate the cell-autonomous expression profile 
induced by RNASET2 in ovarian cancer cells.
in vitro WHOLE GENOME 
trANscrIPtIONAL PrOFILING 
OF cONtrOL ANd rNAsEt2-
OVEXPrEssING HUMAN OVArIAN 
cANcEr cELLs 
As previously reported, using the Hey3Met2 
human ovarian cancer cell line, we found the RNASET2 
gene to possess a remarkable in vivo tumor suppressor 
activity, irrespective of the protein’s catalytic activity [9]. 
Noteworthy, when tested in vitro , the same cell clones 
did not show inhibition of cell proliferation, changes in 
the clonogenic potential, impaired growth in soft agar and 
increase in apoptotic rate. 
As stated in the previous section, although these data 
strongly suggest that RNASET2 might represent a new 
member of the family of TAG/MSG (acting mostly in a 
non-cell autonomous fashion), we could not formally rule 
out a cell-autonomous effect elicited by this gene on the 
cancer cells, which might have escaped detection by our 
panel of in vitro standard assays. We therefore decided to 
carry out a more thorough analysis to shed light on this 
issue.
Accordingly, we defined the expression profile of the 
RNASET2-overexpressing Hey3Met2 cells and compared 
it with that of control cells. An Agilent Whole Human 
Genome Oligo Microarray was employed with total RNA 
extracted from Hey3Met2 clones transfected with wild-
type or a catalytically mutant form of RNASET2 (whose 
cDNA was mutagenized in the two CAS catalytic sites). 
Total RNA from Hey3Met2 cells, transfected with the 
empty vector, was used as a control.
Sixty-five genes were found to be modulated by at 
least one of the two RNASET2 protein forms tested (i.e. 
either wild-type or catalytically dead RNASET2), with a 
fold-induction or repression greater than 2 and a p-value 
smaller than 0.01. These genes were further organized by 
hierarchical clustering using squared Pearson correlation 
into 2 clusters, as shown in figure 1. Overall, for several 
of these genes we noticed a trend for a higher degree 
of change in their expression levels in Hey3met2 cells 
transfected with wild-type rather than catalytically-mutant 
RNASET2 expression vectors. This might, hypothetically, 
suggest  some  influence  of  RNASET2  ribonucleolytic 
Figure  1: Heatmap of genes differentially expressed. 
Modulated genes were organized in 2 clusters by hierarchical 
clustering. Each column corresponds to a single biological 
replicate. Each row represents a gene, with red and green for high 
and low expression levels, respectively.Oncotarget 2011; 2:  477 - 484 479 www.impactjournals.com/oncotarget
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GENE
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FOLd-
cHANGE 
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FOLd-
cHANGE 
MUt
GENE ONtOLOGY
MDK
midkine (neurite 
growth promoting 
factor 2)
-2.5 -2.9
heparin binding; 
glycosaminoglycan binding
MCAM
melanoma cell
adhesion molecule
-3 -2.8 cell adhesion;motility
AREG amphiregulin -2.1 -3.8 growth factor activity-cell invasion
NNMT
nicotinamide 
N-methyltransferase
-4.1 -5.1 cell migration
PLAU
plasminogen 
activator,urokinase
-2.0 -1.2
 wound healing; fibrinolysis 
and degradation of extracellular 
matrix.
DDIT4
DNA-damage-
inducible transcript 4
-4.3 -2.2
CPA4 Carboxypeptidase A4 -3.8 -1.3 peptidase activity;zinc ion binding.
RELB
v-rel
reticuloendotheliosis 
viral oncogene 
homolog B
-2.1 -1.8
DNA binding; transcription factor 
activity; transcription regulator 
activity
JDP2
Jun dimerization 
protein 2
-3.4 -2.4
DNA binding;transcription factor 
activity;transcription regulator 
activity
DMKN dermokine -6.7 -6.2 Rab GTPase binding
PTPRH
protein tyrosine 
phosphatase receptor 
type H
-2 -1.5
phosphoprotein phosphatase 
activity;transmembrane receptor 
protein phosphatase activity
DSE
dermatan sulfate 
epimerase
+2.1 +1.2
racemase and epimerase 
activity;chondroitin-glucuronate 
5-epimerase activity
LIMCD1
LIM and cysteine-rich 
domains 1  
+2.6 +2.3
zinc ion binding;transcription 
factor binding;transcription 
regulator activity
table 1: List of rNAsEt2-modulated genes selected on the basis of fold change, GO analysis and biological relevance.Oncotarget 2011; 2:  477 - 484 480 www.impactjournals.com/oncotarget
activity on the steady state level of these gene’s transcripts.
In order to define the cellular processes/pathways 
affected by RNASET2, all differentially expressed genes 
were cross-referenced to the Gene Ontology (GO) database 
to identify functional categories over-represented in the 
panel of genes associated with the two clusters.
The GO analysis was done at GO FAT level of 
biological process and molecular function, whereas 
Expression Analysis Systematic Explorer (EASE) 
biological theme analysis was carried out online (at http://
david.niaid.nih.gov) using DAVID [11]. The GO survey 
did not show any significant enrichment, probably due to 
the small number of genes analyzed (54 genes in cluster 1 
and 11 genes in cluster 2). Nevertheless, within the above 
mentioned gene set a few associated categories were 
shown to represent biologically relevant process that were 
worth investigating. 
Since TAG/MSG genes are postulated to encode for 
products involved in the cross-talk between the cancer 
cell and the tumor microenvironment [12,13], we selected 
five  RNASET2-responsive genes, mainly because of of 
their involvement in cell adhesion and migration. The five 
selected genes are MDKN, encoding an angiogenic growth 
factor over-expressed in various human malignant tumors 
and recently suggested as a new biomarker for ovarian 
cancer [14-16]; AREG (cell invasion breast cancer), a 
regulator of cancer cells invasiveness which was reported 
to be frequently overexpressed in colon, breast, prostate, 
pancreas, lung and ovarian cancer [17-19]; MCAM, a well 
known marker of poor prognosis in epithelial ovarian 
cancer, whose gene product promotes the growth, invasion 
and metastasic potential of malignant cells [20-22]; PLAU 
(PLasminogen Activator Urokinase-type), which promotes 
fibrinolysis and degradation of extracellular matrix [23]; 
and NNMT (nicotinamide N-methyltransferase), a serum 
tumor marker for colorectal cancer recently identified as 
novel regulator of cell migration [24,25].
Moreover, on the basis of their biological function we 
decided to validate a few genes that were also shown to be 
down-regulated after RNASET2 overexpression. The first 
is DMKN, a gene differentially regulated in inflammatory 
conditions, and whose role in activating Rab5 function 
was recently defined [26]. The genes encoding for the 
transcription factors RELB and JPD2 were also selected, 
due to their involvement in the NF-kB pathway and cell 
proliferation/differentiation, respectively [27-30]. 
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Figure 2: in vitro and in vivo validation of the microarray expression profile for 13 putative RNASET2-responsive genes 
by realtime rt-Pcr. A) qPCR assays were performed for each gene using the same RNA samples from the RNASET2-overexpressing 
Hey3Met2 cells clones used for microarray hybridization. The panel below the graph compares the in vitro expression data from microarray 
hybridization and qPCR assays. B) qPCR expression data for the same genes in tumors grown in vivo in immunocompromized mice 
following s.c. inoculation of RNASET2-transfected and control Hey3Met2 clones.Oncotarget 2011; 2:  477 - 484 481 www.impactjournals.com/oncotarget
The DDIT4 gene was chosen due to its role in RAS-
mediated transformation of ovarian epithelial cells [31]. 
Significantly, transfection of DDIT4 expression vectors in 
immortalized human ovarian surface epithelial cells has 
been shown to render the cells tumorigenic in substitution 
for oncogenic Ras mutations. 
Recent studies have suggested a relation between 
CPA4 gene expression and prostate cancer aggressiveness, 
possibly due to its role in extracellular peptide processing 
[32]. We thus included CPA4 in the panel of genes to be 
further investigated.
The PTPRH gene, encoding a member of the protein 
tyrosine phosphatase (PTP) family [33], was also selected, 
since PTP proteins are known to regulate a variety of 
cellular processes including cell growth, differentiation, 
mitotic cycle, and oncogenic transformation. 
Finally, two genes that were up-regulated by 
RNASET2 were also selected for validation: LMCD1, 
belonging to the category of the LIMD1 tumor suppressor 
gene, and DSE (dermatan sulfate epimerase), whose 
protein product elicits specific cytotoxic T lymphocytes 
responses in cancer patients [34,35]. Table 1 provides a 
list of the thirteen genes selected for validation.
VALIdAtION ANd cOMPArIsON OF 
tHE trANscrIPtIONAL PrOFILEs in 
vitro ANd in vivo
To validate these genes, realtime RT-PCR (qPCR) 
assays were performed on the same RNA samples used 
for microarray hybridization. In order to allow for cross-
references of the expression data, the sequence of all 
primer pairs was designed to span the region of the cDNA 
corresponding to the hybridization probes placed on the 
microarray chip. As shown in figure 2A, the pattern of 
gene expression changes observed following microarray 
hybridization  was  confirmed  by  qPCR  for  most  tested 
genes. The only exception was represented by the DSE 
and PLAU genes, whose expression pattern in Hey3Met2 
cells expressing the catalytically-mutant RNASET2 
protein turned out to be down-regulated by microarray 
hybridization but upregulated by qPCR. However, for 
both genes the observed change in expression pattern 
with respect to control clones was below the chosen 
2-fold threshold for significance (+1.2-fold by microarray 
hybridization vs. -1.43-fold by qPCR for DSE and -1.2-
fold by microarray hybridization vs. + 1.05-fold by qPCR 
for PLAU, respectively). Moreover, for both genes the 
expression pattern observed by qPCR in Hey3Met2 cells 
expressing wild-type RNASET2 was in agreement with 
that observed by microarray hybridization. 
As expected for using a more sensitive test, 
the observed fold-changes in the expression levels 
appeared to be slightly higher for several genes when 
tested by qPCR. For example, the RNASET2-mediated 
downregulation of the CPA4, DMKN and MCAM genes 
that was observed by microarray hybridization turned out 
to be much more evident when assayed by qPCR. Of note, 
the fold-change expression for the RNASET2 gene turned 
out to be much higher by qPCR, in keeping with previous 
expression data obtained by western blot analysis carried 
out on the same clones (data not shown). We next asked 
whether some of these genes could have any relevance 
in  RNASET2-mediated tumor suppression in vivo. To 
this end, total RNA extracted from xenograph tumors [9] 
was used to assess whether the expression pattern was 
congruent with the qPCR data. Clearly at variance with 
the in vitro setting, the in vivo tumor population is rather 
heterogeneous, comprising both human Hey3Met2 cancer 
cells and host-derived murine stromal cells.. The results 
of  this  survey  are  shown  in  figure  2B. As  shown,  the 
RNASET2-mediated changes in the expression levels that 
we previously observed in vitro were not confirmed for 
most tested genes in the in vivo setting. Indeed, significant 
changes in the expression pattern that were found to be in 
agreement with those previously observed in vitro could 
be reported for just three genes, namely LMCD1, DSE and 
RELB. 
As for the remaining genes, whereas some of them 
(i.e. CPA4, MDK and AREG) are almost unresponsive to 
RNASET2 expression in vivo, others showed obvious 
changes in expression pattern mediated by RNASET2, but 
these changes were in the opposite direction with respect 
to those observed in vitro.
FUtUrE dIrEctIONs
Undoubtly, the observed RNASET2-mediated 
modulation of LMCD1, DSE and RELB gene expression 
deserves further investigation, since it has been detected 
in vitro and subsequently confirmed in vivo. These three 
genes thus represent bona fide candidate effector genes 
for  RNASET2-mediated tumor suppression. A panel of 
ovarian cancer cell lines, characterized for RNASET2 
expression levels, is available in our laboratory and will 
be used to investigate the relationship between RNASET2 
levels ,expression of these three genes and putative 
phenotypic outcomes. Furthermore a RNASET2-knock-
down model recently established in our laboratory in the 
OVCAR3 ovarian cancer cell line will further contribute 
to investigate this issue. 
As for the putative mechanisms by which these 
three genes might contribute to RNASET2-mediated 
tumor suppression, it is worth noting that two of them 
show a plausible link with cellular functions related to 
tumor rejection by the immune system. Indeed, it is well 
established that one of the several biological functions 
of this pleiomorphic RNase is the modulation of host 
immune system [8].
Accordingly, the RELB gene has long been 
associated with adaptive immune responses mediated by 
dendritic cells [28,29]. Moreover, since RELB is directly Oncotarget 2011; 2:  477 - 484 482 www.impactjournals.com/oncotarget
involved in the NK-κB pathway, it is tempting to postulate 
a role for RNASET2 in RELB-mediated control of tumor-
associated macrophages (TAM) polarization. In fact, 
tumor progression is thought to involve a gradual switch 
of macrophage polarization from M1 to M2 class, which 
is paralleled by a gradual inhibition of NK-κB activity 
[36]. This role for the NK-κB pathway in macrophage 
polarization might therefore be relevant, considering that 
RNASET2 is apparently able to recruit specific subclass 
of stromal macrophages in the Hey3Met2 ovarian cancer 
model studied by our group [9]. It will be of interest in 
future  studies  to  define  whether  RNASET2  derived 
from cancer cell, could influence , the NK-κB pathway 
by changing the RELB expression levels in cells of 
the monocyte/macrophage lineage. Moreover, due to 
the observed downregulation of RELB  in Hey3Mey2 
cells expressing RNASET2, a cell-autonomous role for 
RNASET2 cannot be completely ruled out, since the 
RELB protein is known to promote cancer cell survival 
by inducing the expression of proteins with anti-apoptotic 
roles, such as Survivin and Bcl-2 [37]. A close inspection 
of the RELB yeast ortologue’ s behaviour in yeast cells 
could be very instructive in this regard.
The second RNASET2-responsive gene that might 
be related to immune cell function is DSE. It encodes 
for dermatan sulfate epimerase, an enzyme involved in 
D-glucuronic acid to L-iduronic acid conversion in the 
dermatan sulphate biosynthetic pathway [38]. The DSE 
gene was originally identified on the basis of the ability of 
its gene product to be recognized with high efficiency by a 
subset of cytotoxic T lymphocytes in certain tumors [35]. 
Moreover, expression of DSE was found to be altered in 
laryngeal cancer specimens when compared to normal 
tissue  samples  [39].  Significantly,  abnormal  dermatane 
sulphate composition has also been reported in both 
ovarian carcinomas and ovarian cancer cell lines [40], 
providing further support for a putative role of DSE in our 
ovarian model. 
As for the third gene whose change in expression level 
was confirmed in vivo (LMCD1), its direct involvement 
in  RNASET2-mediated tumor suppression is rather 
speculative. . LMCD1 encodes for a poorly characterized 
cysteine-rich and LIM domain-containing protein, 
which has been so far implicated in cardiac hypertrophy 
[41]. However, LIM-domain proteins belonging to 
the related CRP family have been described as potent 
tumor suppressor genes [42] and, most importantly, the 
related LIMD1 gene has been recently reported to display 
functional properties reminiscent of tumor antagonizing 
genes [7]. 
Taken together, the results of our studies provides 
a clear indication that investigations of the molecular 
mechanisms through which TAG/MSG carry out their 
biological functions necessitate a thorough comparison 
between the in vitro and in vivo expression patterns. 
Indeed, several genes displaying a biological function 
potentially related to tumor suppression, and thus defined 
as candidate based on their in vitro expression pattern, 
were not validated by subsequent in vivo expression 
profiling.
On the other hand, the fact that the same changes in 
the expression levels of a few genes (i.e. RELB, LIMD1 
and DSE) were observed both in vitro and in vivo deserves 
some comments.. t We rekon that the results gathered in the 
present report highlight some of the limitations inherent in 
the conceptual process of categorizing relevant biological 
processes. In our case, the strict categorization of tumor 
antagonizing genes as genes endorsed with an asymmetric 
behavior (i.e. suppressing tumorigenicity without 
affecting in vitro growth) was clearly dependent on the 
sensitivity of the methodological approach employed. In 
fact, using the highly sensitive microarray analysis some 
genes’ features were detected in a congruent fashion in 
both the in vivo and in vitro.
The three above mentioned genes are therefore 
worth to be investigated in depth, as they could represent 
not only relevant candidates for the carcinogenetic 
process taking place in our ovarian cancer model, but they 
could also be instrumental and paradigmatic of a more 
molecularly-oriented classification of the growing family 
of tumor antagonizing genes.
We reckon that the latter issue is not irrelevant in 
contributing some conceptual and experimental support 
for a more systematic search and characterization of tumor 
antagonizing genes. To this end, it is worth reminding 
that the genome of a cancer cell is mainly characterized 
by DNA losses and given the limited number of tumor 
suppressor genes identified and characterized so far, we 
are probably seeing just the “tip of the iceberg”, with 
a large fraction of genes (including TAGs) protecting 
against malignant growth yet undiscovered.
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